Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin study group

Journal of Clinical Oncology

Volumn 33, Issue 26, 2015, Pages 2857-2862

  Eichenauer, Dennis A ^a   Plütschow, Annette ^a   Fuchs, Michael ^a   Von Tresckow, Bastian ^a   Böll, Boris ^a   Behringer, Karolin ^a   Diehl, Volker ^a   Eich, Hans Theodor ^b   Borchmann, Peter ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; RITUXIMAB; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; EXTENDED FIELD RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INVOLVED FIELD RADIOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RETROSPECTIVE STUDY; SECOND CANCER; TREATMENT RESPONSE; HODGKIN DISEASE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RECURRENCE;

EID: 84949007152     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.4363     Document Type: Article

References (22)

1. Diehl V, Sextro M, Franklin J, et al: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783, 1999
2. Eichenauer DA, Engert A: VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematol Oncol 31:47-50, 2013 (suppl 1)
3. Eichenauer DA, Engert A, Andre M, et al: Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii70-iii75, 2014 (suppl 3)
4. Hoppe RT, Advani RH, Ai WZ, et al: Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:589-597, 2012
5. Solanki AA, LeMieux MH, Chiu BC, et al: Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy. PLoS One 8:e75336, 2013
6. Chen RC, Chin MS, Ng AK, et al: Early-stage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28:136-141, 2010
7. Nogová L, Reineke T, Eich HT, et al: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-1687, 2005
8. Savage KJ, Skinnider B, Al-Mansour M, et al: Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118:4585-4590, 2011
9. Dühmke E, Franklin J, Pfreundschuh M, et al: Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905-2914, 2001
10. Engert A, Franklin J, Eich HT, et al: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 25:3495-3502, 2007
11. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
12. Behringer K, Goergen H, Hitz F, et al: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An openlabel, randomised, non-inferiority trial. Lancet 385: 1418-1427, 2015
13. Eichenauer DA, Fuchs M, Pluetschow A, et al: Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 118:4363-4365, 2011
14. Nogová L, Reineke T, Brillant C, et al: Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439, 2008
15. Advani RH, Horning SJ, Hoppe RT, et al: Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 32:912-918, 2014
16. Koh ES, Tran TH, Heydarian M, et al: A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: Reduction in normal tissue dose and second cancer risk. Radiat Oncol 2:13, 2007
17. Hodgson DC, Koh ES, Tran TH, et al: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576-2586, 2007
18. Al-Mansour M, Connors JM, Gascoyne RD, et al: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 28:793-799, 2010
19. Biasoli I, Stamatoullas A, Meignin V, et al: Nodular, lymphocyte-predominant Hodgkin lymphoma: A long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 116:631-639, 2010
20. Xing KH, Connors JM, Lai A, et al: Advancedstage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: A matched pair outcome analysis. Blood 123:3567-3573, 2014
21. Hartmann S, Eichenauer DA, Plütschow A, et al: The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG). Blood 122:4246-4252, 2013
22. Shet T, Panjwani P, Epari S, et al: A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma 20:1-8, 2014